Cogint

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 17,899,698 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 3,030,302 shares of its common stock at an exercise price of $0.01 per share. The shares of common stock sold include 2,730,000 shares pursuant to the option to purchase additional shares granted by Cogent to the underwriters, which option was exercised in full. The public offering price of each share of common stock was $8.25 and the public offering price of each pre-funded warrant was $8.24. The aggregate gross proceeds to Cogent from this offering were approximately $172.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15,169,698 shares of its common stock, offered at a public offering price of $8.25 per share. In addition, in lieu of issuing common stock to certain investors, Cogent is offering pre-funded warrants to purchase 3,030,302 shares of its common stock at a purchase price of $8.24 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 exercise price per share of each pre-funded warrant. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other estimated offering expenses, upsized from $125 million. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 2,730,000 shares of its common stock at the public offering price less underwriting discounts. All of the shares of common stock and pre-funded warrants in the offering are being sold by Cogent. The offering is expected to close on or about June 16, 2022, subject to customary closing conditions.

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants

Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.

Cogent (COGT) Surges on Robust Data from Mastocytosis Study

Today, investors in Cogent Biosciences and COGT stock have some promising clinical trial results to look at, as this stock soars. The post Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data appeared first on InvestorPlace.

Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data

Cogent Biosciences, Inc. (NASDAQ: COGT) shares are trading higher after the company reported initial data from its ongoing Phase 2 APEX clinical trial. All patients treated with bezuclastinib achieved greater than or equal to 50% reduction in serum tryptase, with a median reduction of 89%,.

Why Shares Of Cogent Biosciences Are Trading Higher

All patients treated with bezuclastinib achieved ≥ 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

– Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress – Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress

Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET

Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM)

Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress

Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on Tuesday, May 10, 2022 at 3:30 p.m. ET.

Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium

New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors

Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event

APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients

Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be hosted April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022

Cogent Biosciences Provides 2022 Corporate Guidance

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results

Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021

Puma Biotechnology

Harpoon Therapeutics Inc

MarketWise

Surrozen

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Sizzling Buy-Rated Biotechs Highlight 5 Top Stocks Under $10

Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration

Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference

Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results

Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021

Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021

Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results

News for Cogint Stock (COGT)